THE EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTHCARE (EDQM)



European Directorate | Direction européenne for the Quality of Medicines | de la qualité du médicament & HealthCare | & soins de santé

COUNCIL OF EUROPE



CONSEIL DE L'EUROPE

Recent developments in Ph. Eur. general texts regarding analytical methods


FIMEA (Live Webinar) Date: 31 October 2023



© EDQM, Council of Europe, 2023. All rights reserved.

Who's talking ?

Mr Bruno SPIELDENNER





Structure of the Ph. Eur.



Ph. Eur.: Content and structure



General notices

- Essential reading
- Apply to all texts
- Address general topics
- Provide basic information
- Include rules to understand texts, conventional expressions

General monographs

Dosage form monographs

- Classes of substances/medicinal products
- Mandatory for all substances/products
 within scope of their definition
- Aspects that cannot be included in each individual monograph
- Not cross-referenced in individual monographs (exceptions)



Ph. Eur. Reference standards / preparations & reagents

General chapters & general texts

- avoid repeating standard procedures or requirements in each monograph; aspects that cannot be treated in each monograph
- become mandatory when referred to in a monograph
- provide standard analytical procedures; guidance

Individual monographs

- Specific but not a stand alone text
- Analytical procedures and acceptance criteria represent required quality standards
- Based on approved specifications backed up by batch data
- Reliance on manufacturers' feedback (public consultation)

General Notices – answers to a lot of questions!

- Such as:
 - What does compliance mean?
 - What is mandatory?
 - What to do when implementing a pharmacopoeial procedure?
 - What about alternative analytical procedures?
 - What about waiving of tests?
 - Why two identification tests ... sometimes?
 - Human and/or veterinary use?

And many more...

On demand webinar is available for learning more on the recent changes <u>https://www.edqm.eu/en/-/getting-the-big-picture-what-has-changed-in-the-ph.-eur.-general-notices</u>



Revised in supplement 10.7

General monographs

(SEIL DE L'EUROPE	EUROPEAN PHARMACOPOEIA			
E Docu en Fra Gen	OME 10TH EDITION - ARC ment ançais PDF eral Notices apply the information s	Check which general monograph(s) applies!	Whenever a monograph is used, it is essential to ascertain whether there is a general monograph applicable to the product in question. The European Pharmacopocia contains a number of general monographs covering classes of products. These general monographs give requirements that are applicable to all products in the given class or, in some cases, to any product in the given class for which there is a specific monograph in the Pharmacopoeia (see 1. General Notices, General monographs). Where no restriction on the scope of a general monograph for the product in the Pharmacopoeia. The general monographs listed below are published in the General monographs section (unless otherwise stated). This list is updated where necessary and republished in each supplement. Allergen products (1063) Chemical precursors for radiopharmaceutical preparations (2902) Dosage Forms (published in the Dosage forms section or the Homoeopathic preparations section, as appropriate)		
		API	Medicinal product		
EXAMPLES	Ibuprofen (0721)	Substances for pharmaceutical use (2034)	Pharmaceutical preparations (2619) <i>Capsules (0016)</i>		
7X3	Azithromycin (1649)	Substances for pharmaceutical use (2034) + Products of fermentation (1468)	Pharmaceutical preparations (2619) <i>Tablets (0478)</i>		



SUBSTANCES **Example: General monograph 2034** FOR PHARMACEUTICAL USE

used in pharmacies only, provided it can be demonstrated that the substance or preparation is fully traceable to a batch elemental impurities (e.g. as included in the ICH Q3D monograph that the substance for pharmaceutical use: Related substances: defining thresholds and refering to 5.10. Control of The identity of elemental impurities derived from intentionally ply to the as a direct ge substances where appl added catalysts and reagents is known, and strategies for requiremen recombinar controlling them should be established using the principles of .4.24 or anot impurities in substances for pharmaceutical use (ICH Q3A) is obtained ination of a spongiform oss on drying i risk management. challenge, nt is taken into the substance with the rewith risk of Elemental impurities. Permitted daily exposures for encephalopat wherever such is a substan nce criteria elemental impurities (e.g. as included in the ICH Q3D whether or nces for by tradition logical quality technology, Elemental impurities: considered during guideline, the principles of which are reproduced in substances fo microbiological with the req inces subject to general chapter 5.20. Elemental impurities) apply to the of fermental nature of the production with risk management. If solvents are otance criteria quality. In add medicinal product. Individual monographs on substances for nufacture of are taken into a 5.20 Elemental impurities (= principles riate sterilisation pharmaceutical use therefore do not contain specifications for ubstance for The identity of sterility added catalysts of ICH Q3D guideline) applies for elemental impurities unless otherwise prescribed. controlling ther bacterial risk manageme oxin-free grad f parenteral medicinal products out a furthe form or grade **Residual solvents** are limited according to the principles complies with al monograph functionalitynendations defined in chapter 5.4, using general method 2.4.24 or another the test for properties that and subseque suitable method. Where a quantitative determination of a stified rather from it. Residual solvents: refers to 5.4 pyrogen-free Powdered sub: utical use residual solvent is carried out and a test for loss on drying is degree of fine and test method Residual solvents (=ICH Q3C); the proved by the Compacted su est validation not carried out, the content of residual solvent is taken into size or to obta st for bacterial a substance wi chapter applies to APIs and excipients account for calculation of the assay content of the substance, Coated active properties (e.g substance coat characteristics the specific optical rotation and the specific absorbance. ing processes Granulated ac in scope of 2034 toxin-free, size and/or for manufacture granulation dire r other dosage "N-Nitrosamines. As many N-nitrosamines are classified as probable cified in ar →often no specific test in monograph If substances are comply with the where no such m human carcinogens, manufacturers stances for Where active sub are expected to evaluate the potential risk of N-nitrosamine ethods are to produce, for e the processing is formation and contamination occurring throughout their manufacturing p **NEW:** *N*-Nitrosamines regarded as into and nationa manufacturing process and during storage. If the risk is confirmed, statements product. mprehensiv poeia only CHARACTERS manufacturers should mitigate as much as possible the presence te complianc The statements idatory. Any of *N*-nitrosamines – for example by modifying the manufacturing about the solub nendations eia, the interpreted in a s ; the package, are given for info process – and a control strategy should be implemented to detect COUNCIL OF EUROP and control these impurities. General chapter 2.5.42 N-Nitrosamines © EDQM, Council of Europe, 2023. All rights reserved. 8

in active substances is available to assist manufacturers."

2

Example: General monograph 2619 PHARMACEUTICAL PREPARATIONS

- reference source of standards in the European Pharmacopoeia on active substances, excipients and dosage forms, which are to be applied in the manufacture/preparation of pharmaceuticals
- Microbiological quality: links given to the relevant general texts (5.1.1, 5.1.3, 5.1.4, 5.1.8)
- Elemental impurities: refers to general text 5.20 (= principles of ICH Q3D guideline) rendered mandatory according to its scope. For products outside scope, EI are a risk that needs to be managed
- **NEW**: *N*-Nitrosamines

9 © EDQM, Council of Europe, 2023. All rights reserved.

use (2034), Essential oils (2098), Herbal drug extracts (0765), Herbal drugs (1433), Herbal drug preparations (1434), Herbal drugs for homeopathic preparations (2045), Mother tinctures for homeopathic preparations (2029), Methods of preparation of homeopathic stocks and potentisation (2371), Products of fermentation (1468), Products of recombinant DNA technology (0784), Vegetable fatty oils (1579). In addition, where specific monographs exist, the quality of the active substances and excipients used complies with the

corresponding monographs. Where no specific monographs exist, the required quality must be defined, taking into account the intended use and the involved risk.

Methods used for the purpose of stability testing for all relevant characteristics of the preparation are validated as stability indicating, i.e. the methods allow the quantification of the relevant degradation products and physical characteristic changes.

ESTS						
elevant	tests	to	apply	in	order	

Relevant tests to apply in order to ensure the appropriate quality of a particular dosage form are described in the specific dosage form monographs.

Where it is not practical, for unlicensed pharmaceutical preparations, to carry out the tests (e.g. batch size, time

Unless otherwise justified and authorised, contents of active substances and specific excipients such as preservatives are determined in pharmaceutical preparations. Limits must be defined and justified.

Suitable and validated methods are used. If assay methods prescribed in the respective active substance monographs are used, it must be demonstrated that they are not affected by the presence of the excipients and/or by the formulation.

Reference standards. See Tests

LABELLING AND STORAGE

Elemental impurities. General chapter 5.20. *Elemental impurities* applies to pharmaceutical preparations except products for veterinary use, unlicensed preparations and other products that are excluded from the scope of this chapter.

For pharmaceutical preparations outside the scope of general chapter 5.20, manufacturers of these products remain responsible for controlling the levels of elemental impurities using the principles of risk management.

If appropriate, testing is performed using suitable analytical procedures according to general chapter 2.4.20. Determination of elemental impurities.

"*N*-Nitrosamines. As many *N*-nitrosamines are classified as probable human carcinogens, manufacturers of medicinal products, except products for veterinary use only and unlicensed pharmaceutical preparations are expected to evaluate the potential risk of *N*-nitrosamine formation and contamination occurring throughout their manufacturing process and throughout their shelf-life, according to the requirements of the relevant competent authorities. If the risk is confirmed, manufacturers should mitigate as much as possible the presence of *N*-nitrosamines – for example by modifying the manufacturing process – and a control strategy must be implemented to detect and control these impurities. General chapter 2.5.42 *N*-Nitrosamines in active substances is available to assist manufacturers."



General chapters

	✓ 05 General Texts Azith	
	5.1. General texts on microbiology	(number of texts from Suppl. 11.2)
	5.2. General texts on biological products	
	5.3. Statistical analysis of results of biological assays and tests	
	5.4. Residual solvents trideo	Conord
	5.5. Alcoholimetric tables Semi-	General
	5.6. Assay of interferons	notices
	5.7. Table of physical characteristics of radionuclides mentioned in	
able of contents	5.8. Pharmacopoeial harmonisation Appendix	General
Document PDP en Français	5.9. Polymorphism Solub	chapters 339
European Pharmacopoeia 10.0 General Notices	5.10. Control of impurities in substances for pharmaceutical use	
	5.11. Characters section in monographs	
> 00 Introduction	5.12. Reference standards	General
01 General notices	5.14. Gene transfer medicinal products for human use	monographs
✓ 02 Methods of analysis	5.15. Functionality-related characteristics of excipients	53
2.1. Apparatus	5.16. Crystallinity TESTS	
2.2. Physical and physicochemical methods	5.17. Recommendations on methods for dosage forms testing lut	
2.3. Identification	5.18. Methods of pretreatment for preparing traditional Chinese d	
2.4. Limit tests	5.19. Extemporaneous preparation of radiopharmaceuticals PH (2	individual monographs
2.5. Assays This glossary provements on Phase	5.20. Elemental impurities	
2.6. Biological tests publications or construction	5.21. Chemometric methods applied to analytical data	2442
2.7. Biological assays	5.22. Names of herbal drugs used in traditional Chinese medicine	
2.8. Methods in pharmacognosy	5.23. Monographs on herbal drug extracts (information chapter)	
2.9. Pharmaceutical technical procedures	5.24. Chemical imaging Test so	
03 Materials for containers and containers	5.25. Process analytical technology	
O4 Reagents Basis	5.28. Multivariate statistical process control	
Basis is an altern		



General chapters

Section 2: Methods of analysis



Give general requirements for equipment and procedures
Editorial convenience: avoid repetition in each monograph
Provide standard procedures that can be used where there is no monograph (with product specific validation)

Section 5: General texts



- Informative texts
- Specific to certain topics (e.g. microbiology, chemometrics)
- In some cases, reproduces the principles of regulatory guidelines

➔ Not mandatory on their own

→ When referred to in a (general or individual) monograph, they become part of the standard

- ✓ 2.2.24 IR spectrophotometry, referred in many ID tests → Mandatory application
- ✓ 2.2.48 Raman spectroscopy, no monograph reference For guidance can be mentioned in applications but has no mandatory character
- → Some chapters are only informative or provide examples → This is clearly indicated



General Chapters in the Ph. Eur.



Recent achievements : revised/new GMs

(Not exhaustive)

- N-Nitrosamines in active substances, 2.5.42
- Balances for analytical purposes, 2.1.7
- Raman spectroscopy, 2.2.48
- ★ Chromatographic separation techniques, 2.2.46



- Cell-based assays for potency determination of TNF-alpha antagonists, 2.7.26
- Osmolality, 2.2.35





Balances for analytical purposes, 2.1.7 SUPPL. 10.6, 01/2022




- Applicable for all weighings described in Ph. Eur. texts
- Fitting in the international regulatory landscape (aligned with USP <41> & <1251>)
- Giving recommendations for installation and location
- Including lifecycle management of balances:
 - Qualification;
 - Performance checks, i.e. routine tests for evaluating its error (sensitivity and repeatability tests);
 - internal adjustments.
- Introducing the concepts of smallest net weight (user) and minimum weight (instrument)

Further reading available: <u>https://pbiosn.edqm.eu/app/pbiosn/content/default/2022-</u> <u>1_Weighing_according_to_the_European_Pharmacopoeia.pdf</u>



Balances for analytical purposes, 2.1.7: Minimum weight

- Instrument parameter; linked to repeatability performance (st. dev.)
 →Varies with time and external factors
 →m_{snw} must be superior to m_{min} (at least equal=high risk)
- In an ideal case: $m_{min} = 2000 \times s = 820 \times d$ (readability)



edon

for the Quality de la quality

Minimum weight

Chromatographic separation techniques (2.2.46)


Widely applicable across chromatography chapters

- Definitions and calculation methods for common parameters (peak, retention time, resolution, etc.)
- System suitability requirements for LC and GC procedures:
 - system repeatability (assay)
 - system sensitivity (tests)
 - peak symmetry [≠ normalisation] (tests and assays)

complementing those given in the individual monographs.

Describes framework for adjustments of chromatographic conditions

Revised chapter (harmonised with USP and JP), Ph. Eur. 11th Edition, July 2022



for the Quality of Medicines & HealthCare & soins de sa

*list not exhaustive (further adjustmer flow rate, injection volume)

Adjustments and requirements-compromise at PDG

Chapter 2.2.46 provides the framework for adjustments that can be performed without revalidation

- Column dimensions, permitted modifications (11.0)
 For TPP: L/dp within -25 % to +50 % of the prescribed L/dp ratio (change from HPLC to UHPLC possible)
 For SPP: other L/dp provided N within 25 % to + 50 % of the original N
- Stationary phase of column

o no change to identity of substituent e.g. no replacement C18 ↔ C8 (older text)
 o similar physico-chemical characteristics + similar surface modification and extent of modification (11.0)

edon

Requirements

- Former text: SST requirements must be fulfilled when chromatographic conditions are adjusted and adjustments possible to comply with SST
- Revised text (11.0):

SST compliant :

- symmetry (A_s) of peak used for quantitation OK (general SST)
- sensitivity (S/N) at reporting threshold OK (general SST)
- + ADDITIONAL REQUIREMENTS:
- selectivity of specified impurities equivalent
- elution order


➤Valid for isocratic and gradient systems





More flexibility but more safeguards

Key principle of the Ph. Eur.: no successive changes





19 © EDQM, Council of Europe, 2023. All rights reserved.

IMPLEMENTATION OF GENERAL CHAPTER 2.2.46 FOR EXISTING MONOGRAPHS

Revised chapter (*i.e. 2.2.46*) applies to all individual monographs since 1.01.2023.

(Via cross references in the instrumental chapters on LC (2.2.29), GC (2.2.30), etc.)

As mentioned in the *General Notices*, 'General chapters become mandatory when referred to in a monograph, unless the wording clearly indicates that it is not the intention to make the text referred to mandatory but rather to cite it for information.'

[...]

Reference procedure = Ph. Eur. procedure




IMPLEMENTATION OF GENERAL CHAPTER 2.2.46 FOR IN-HOUSE PROCEDURES

When using an in-house analytical procedure, i.e. a nonpharmacopoeial analytical procedure, general chapter *2.2.46* is not mandatory.

Any reference to and/or application of general chapter *2.2.46* for quality control of substances or medicinal products using chromatographic procedures not described in relevant Ph. Eur. monographs is subject to approval by the competent authority as part of the assessment of a marketing authorisation application.



Ph. Eur. Concepts Related to Analytical Procedures



The analytical procedures given in an individual monograph have been **validated** in accordance with accepted scientific practice and recommendations on analytical validation. Unless otherwise stated in the individual monograph or in the corresponding general chapter, validation of these procedures by the user is not required.

When **implementing** a Ph. Eur. analytical procedure, the user must assess whether and to what extent its suitability under the actual conditions of use needs to be demonstrated according to relevant monographs, general chapters and quality systems.


The tests and assays described are the official analytical procedures upon which the standards of the Ph. Eur. are based. With the agreement of the competent authority, **alternative analytical procedures** may be used for control purposes, provided that they enable an unequivocal decision to be made as to whether compliance with the standards of the monographs would be achieved if the official procedures were used. In the event of doubt or dispute, the analytical procedures of the Ph. Eur. are alone authoritative.



Implementation of pharmacopoeial procedures, 5.26


- Aim: to provide guidance on setting up an approach for implementation
- NEW 11th Ed., 01/2023

• « For information » chapter; other approaches may be appropriate





5.26 IMPLEMENTATION EXAMPLES





Comparability of alternative analytical procedures, 5.27

✓ Flexibility in the Ph. Eur., extract of the General Notices (1.1.2.5)

"The tests and assays described are the official analytical procedures upon which the standards of the Ph. Eur. are based. With the agreement of the competent authority, alternative analytical procedures may be used for control purposes, provided that they enable an unequivocal decision to be made as to whether compliance with the standards of the monographs would be achieved if the official procedures were used. In the event of doubt or dispute, the analytical procedures of the Ph. Eur. are alone authoritative."

✓ Users' responsibility to demonstrate comparability to the satisfaction of the *competent authority*

✓ Compliance required, but alternative procedures may be used: same pass/fail decision

✓ The pharmacopoeial procedure is the reference procedure



Just recently adopted by the European Pharmacopoeia Commission

Principle

- Published for information
- Guidance on some possible approaches
 Thin line between sufficient guidance and restrictive reguirements

Scope


 Cases where a pharmacopoeial (official) analytical procedure, as referenced in an individual monograph, would be replaced by an alternative ("in-house") analytical procedure

Not in scope


 Development of new analytical procedures
 Application of pharmacopoeial analytical procedures to articles not covered by Ph. Eur.



Process for comparability, 5.27



Process





Study design


- Based on the outcome of the comparability assessment
- Considers special cases where testing in a head-to-head format is not feasible

Study protocol

- Is established on the basis of the study design
- Covers selection of samples and sample size, APPCs to be included and method for statistical evaluation of data
- Includes definition of comparability through setting of equivalence margin(s) and acceptance criteria and their justification

• Study report:

 summarises the results and conclusion of the comparability study, as well as other relevant information (e.g. deviations from study protocol, newly obtained information on the procedure(s) and or tested samples)




Parameter / Criterion 1
Parameter /Criterion 2
Parameter /Criterion 3
Parameter / Criterion 4
Parameter / Criterion 5





Statistical evaluation of results


- Step 1. Data description
- Step 2. Statistical assumptions
- Step 3. Equivalence testing



- For quantitative results Comparison of two group means: <u>two one-sided t-tests (TOST) method</u>
- For results spreading over a wider range than those obtained at a single level, a regression approach (e.g. Deming regression, bivariate least squares regression)
- Other approaches may be appropriate
- Pass/Fail criterion is key




Typical outcomes of a comparability study





Statistical evaluation of results



In cases where the comparability cannot be accepted directly, certain flexibility is present:


- available data may be reviewed and if bias and/or variability is observed and steps taken to reduce it, the assessment may be relaunched, including e.g. performing additional experiments.

This possibility needs to be clearly defined in the study protocol

E.g. Case 3: If the root cause for the spread of the results can be found, and better precision reached in a repeated test, the outcome would change to accepted.



Lifecycle of the pharmacopoeial procedure



- If a user considers the alternative analytical procedure to bring significant improvement for the quality of the article, they are encouraged to contact EDQM and/or submit a request for a revision
- In the event of a problem with a pharmacopoeial procedure (e.g. implementation difficulties), NPA or EDQM should be contacted and if confirmed, this may result in a revision → inadequate method renders comparability impossible, hence not a case for an alternative procedure





Some updates in the pipeline



Tetermination of elemental impurities, 2.4.20 (after Pharmeuropa)


- * Particulate contamination: sub-visible particles, 2.9.19 (after Pharmeuropa)
- Design of experiments, 5.33 (after Pharmeuropa)
- **★** Capillary electrophoresis (in Pharmeuropa 35.3)
- \bigstar Disintegration of tablets and capsules, 2.9.1 (in Pharmeuropa 35.2)
- Flow cytometry, 2.7.24 (in Pharmeuropa 35.4)
- *N*-Nitrosamines in active substances <u>& medicinal products</u>, 2.5.42 (prepared for Pharmeuropa)



34 © EDQM, Council of Europe, 2023. All rights reserved.

Recent major additions on the work program NON EXHAUSTIVE

- High Throughput Sequencing for the detection of extraneous agents in biological products (2.6.41)
- Evaporative light scattering detection, 2.2.62
- Charged aerosol detection, 2.2.69
- Identification and control of residual solvents, 2.4.24
 - > Alignment with ICH Q3C(R8) and general revision
- Cell-based preparations, 5.32
- Recombinant viral-vectored vaccines for human use, 5.37
- Quality aspects for data analysis, 5.38
 - Framework to ensure that the data used for analysis, decision making and subsequent actions is reliable



DADING...




Update on strategy

Medicinal product monographs



35 © EDQM, Council of Europe, 2023. All rights reserved.

Medicinal product monographs (chemically defined API)





General policy and approaches

- General policies are captured in the <u>Technical Guide</u> for the elaboration of monographs on medicinal products containing chemically defined active substances (3rd Edition, 2023)
- Recent updates of the guide include:
 - $\circ~$ elaboration of combination medicinal products
 - policy on repeatability criterion (Assay/Dissolution) RSD value of 1.0% (n=6) as a general rule confirmed after the trial period (ended in March 2023)
 - indication of the strength(s) of the medicinal product considered during the elaboration of the monograph is provided to users in the EDQM Knowledge database (for information) once a monograph is published (FAQ, March 2023)



 Policy is evolving to best tackle the needs and reflect the regulatory requirements and scientific progress



Update on strategy

Other topics



38 © EDQM, Council of Europe, 2023. All rights reserved.

New activities / new working parties

- AQbD : Assess the feasibility and impact of incorporating analytical procedures developed using the concepts of AQbD in Ph. Eur. monographs
- EXS (Excipient strategy): Identify and discuss best possible approach(es) to address the quality and the standard setting process of excipients for pharmaceutical use
- mRNAVAC : already 3 new general texts on the work programme, addressing aspects related to the production and control of mRNA vaccines and their components
- Nano(medicines) : Drafting and revision of texts in the field of nanomedicines
- BACT(eriophages) : general text back from public consultation *Phage therapy active substances and medicinal products for human and veterinary use* (5.31)



Numerous technical decisions made and texts approved e.g.:

- <u>Ph. Eur. allows the use of recombinant factor C for control of bacterial</u> <u>endotoxins in water monographs</u>
- EDQM publishes 2nd edition of Herbal Guide
- <u>Ph. Eur. Commission keeps pace with veterinary vaccine development</u> <u>efforts</u>
- Ph. Eur. Commission kicks off elaboration of three general texts on mRNA vaccines and components
- <u>The future of pyrogenicity testing: new approaches discussed at joint</u> <u>EDQM-EPAA event</u>
- <u>Ph. Eur. Commission adopts revised general monographs 2034 and</u> 2619 after inclusion of new paragraph on control of N-nitrosamines
- <u>Revised general chapter on rubber closures published in the Ph. Eur.</u> <u>Supplement 11.1</u>



Join us in paving the way for the future...







BE PART OF A DYNAMIC COMMUNITY OF EXPERTS

JOIN THE

NETWORK!











Thank you for your attention



Stay connected with the EDQM

EDQM Newsletter: https://go.edqm.eu/Newsletter LinkedIn: https://www.linkedin.com/company/edqm/ Twitter: @edqm_news Facebook: @EDQMCouncilofEurope

